American Society of Hirudotherapy

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite

Research article published in Journal of cardiothoracic and vascular anesthesia (2020)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentGoswami A et al. · Journal of cardiothoracic and vascular anesthesia, 2020

Abstract

Anticoagulation is an essential component for patients undergoing cardiopulmonary bypass or extracorporeal membrane oxygenation and for those with ventricular assist devices. However, thrombosis and bleeding are common complications. Heparin continues to be the agent of choice for most patients, likely owing to practitioners' comfort and experience and the ease with which the drug's effects can be reversed. However, especially in pediatric cardiac surgery, there is increasing interest in using bivalirudin as the primary anticoagulant. This drug circumvents certain problems with heparin administration, such as heparin resistance and heparin-induced thrombocytopenia, but it comes with additional challenges. In this manuscript, the authors review the literature on the emerging role of bivalirudin in pediatric cardiac surgery, including its use with cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. Moreover, they provide an overview of bivalirudin's pharmacodynamics and monitoring methods.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiac Surgical ProceduresCardiologyCardiopulmonary BypassChildHeparinHirudinsHumansPeptide FragmentsRecombinant Proteins

Summary

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.

Why This Matters for Hirudotherapy

This review examines the emerging role of bivalirudin as a primary anticoagulant in pediatric cardiac surgery, cardiopulmonary bypass, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology, providing an overview of its pharmacodynamics and monitoring methods. The abstract notes increasing interest in bivalirudin to circumvent heparin resistance and heparin-induced thrombocytopenia, while acknowledging it introduces additional challenges. The abstract makes no mention of hirudin, leeches, or any relationship to hirudotherapy, so no defensible ASH connection exists based on this source. As a review of existing literature, it does not generate new clinical data.

Citation

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite

Goswami A et al. · Journal of cardiothoracic and vascular anesthesia, 2020

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.